CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
1.06
2.91%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-4.61)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.39)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.03
Open 1.04
1-Year Change -65.1%
Day's Range 1.01 - 1.06
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 11, 2024 1.03 0.00 0.00% 1.03 1.05 0.99
Dec 10, 2024 1.06 -0.08 -7.02% 1.14 1.14 1.04
Dec 9, 2024 1.12 0.03 2.75% 1.09 1.17 1.07
Dec 6, 2024 1.08 0.01 0.93% 1.07 1.09 1.05
Dec 5, 2024 1.07 0.02 1.90% 1.05 1.10 1.05
Dec 4, 2024 1.09 -0.06 -5.22% 1.15 1.20 1.06
Dec 3, 2024 1.12 0.10 9.80% 1.02 1.12 1.01
Dec 2, 2024 1.05 0.03 2.94% 1.02 1.06 1.00
Nov 29, 2024 1.01 0.00 0.00% 1.01 1.04 0.98
Nov 27, 2024 0.99 0.12 13.79% 0.87 1.01 0.87
Nov 26, 2024 0.86 0.01 1.18% 0.85 0.87 0.83
Nov 25, 2024 0.86 -0.02 -2.27% 0.88 0.93 0.85
Nov 22, 2024 0.86 -0.01 -1.15% 0.87 0.90 0.78
Nov 21, 2024 0.88 -0.03 -3.30% 0.91 0.91 0.86
Nov 20, 2024 0.92 -0.06 -6.12% 0.98 1.01 0.90
Nov 19, 2024 0.98 -0.06 -5.77% 1.04 1.04 0.95
Nov 18, 2024 1.05 -0.08 -7.08% 1.13 1.15 1.02
Nov 15, 2024 1.13 -0.05 -4.24% 1.18 1.18 1.07
Nov 14, 2024 1.15 -0.12 -9.45% 1.27 1.27 1.13
Nov 13, 2024 1.27 0.02 1.60% 1.25 1.29 1.23

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Allakos Inc. Company profile

About Allakos Inc

Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Allakos Inc revenues was not reported. Net loss increased 76% to $269.9M. Higher net loss reflects Research and Development - Balancing increase of 88% to $176.5M (expense), General and Administrative - Balancing increase of 49% to $44.2M (expense), Stock-based Compensation in SGA increase of 42% to $31M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.10 to -$5.01.

Industry: Bio Therapeutic Drugs

825 Industrial Road
Suite 500
SAN CARLOS
CALIFORNIA 94070
US

People also watch

Gold

2,688.13 Price
-1.080% 1D Chg, %
Long position overnight fee -0.0160%
Short position overnight fee 0.0078%
Overnight fee time 22:00 (UTC)
Spread 0.30

ETH/USD

3,895.13 Price
+1.640% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

99,473.90 Price
-2.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Oil - Crude

69.70 Price
-0.440% 1D Chg, %
Long position overnight fee 0.0085%
Short position overnight fee -0.0305%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading